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Introduction
The etiology of childhood pancreatitis is known to be
associated with trauma, gallstones, drugs, hypercal-
cemia, hypertriglyceridemia or idiopathic causes. Various
drugs, including azathioprine, cimetidine, erythromy-
cin, furosemide, hydrochlorothiazide, interferon-α,
mesalazine, methyldopa, metronidazole, tetracycline,
valproate, and asparaginase have been found to induce
acute pancreatitis.1 Ifosfamide (IFOS) is an active drug
against a variety of neoplasms, including rhabdomyosar-
coma, non-rhabdomyosarcoma soft tissue sarcoma, os-
teosarcoma, and neuroblastoma.2 It is relatively well
tolerated in most patients. However, its side effects,
such as arrhythmias, heart failure, severe encephalopa-
thy and hemorrhagic cystitis might be fatal.3 Its other
known side effects include myelosuppression, nephro-
toxicity, neurotoxicity, Fanconi syndrome and psy-
chosis.4,5 Only 2 cases of IFOS-induced pancreatitis
have been reported previously.5,6 Here, we present a
pediatric patient with IFOS-induced pancreatitis and
compare the clinical characteristics of these 3 cases.
Case Report
A 9-year-old boy with osteosarcoma over the left prox-
imal tibia diagnosed in June 2004 received chemo-
therapy at the Pediatric Department, Taipei Veterans
General Hospital. The chemotherapeutic protocol
adopted at our hospital for nonmetastatic osteosarcoma
over limbs comprises 4 drugs, including high-dose
methotrexate, cisplatin, doxorubicin and IFOS.
The dosage of IFOS was 3 g/m2/day continuous
drip for 5 days, for 2 courses of neoadjuvant chemo-
therapy. The patient underwent wide resection with
limb salvage surgery in October 2004, and then adju-
vant chemotherapy was commenced. In November
2004, while IFOS was being administered for the 3rd
time, he complained of abdominal fullness, abdominal
discomfort and nausea during infusion of drug. Due
to persistent abdominal pain and bile-stained vomiting
1 day after the end of IFOS infusion, kidney, ureter
and bladder (KUB) X-ray study, serum amylase, and
lipase were checked. The result of KUB showed pres-
ence of colon cutoff sign (Figure 1A). Serum amylase
and lipase were 1,173 U/L (normal, < 180 U/L) and
5,027 U/L (normal, < 190 U/L), respectively. The
other laboratory results were 75 mg/dL for serum tri-
glyceride (normal range, 20–200 mg/dL), and normal
for aspartate transaminase and alanine transaminase.
Abdominal computed tomography (CT) was performed
and revealed swelling of pancreas with peripancreatic
fat stranding. Fluid accumulated in the peripancreatic
area, lesser sac, paraduodenal and left anterior pararenal
space. The findings were compatible with acute pan-
creatitis, grade E (Balthazar’s severity grade) (Figure 1B
and C). After supportive treatment and total parenteral
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nutrition for 4 days, the patient’s condition improved
quickly. The level of amylase/lipase returned to normal
10 days later.
The dosage of subsequent IFOS was reduced to
2.4 g/m2/day for 5 consecutive days due to severe
myelosuppression. The administration of a 4th and 5th
course of IFOS was smooth in February 2005 and
May 2005. Follow-up amylase/lipase levels in early
June were 81/46 U/L. A 6th course of IFOS was pre-
scribed in late June 2005. Vomiting and epigastralgia
developed 7 days after the end of infusion. Serum 
amylase/lipase levels were within normal limits (52 
and 50 U/L, respectively), and abdominal sonography
revealed no abnormal findings. The patient then suf-
fered from neutropenic fever and received antibiotic
treatment with meropenem. Amphotericin B was also
prescribed for a total of 21 days when stool culture
yielded Candida glabrata.
Vomiting and abdominal pain developed again in
late August 2005, 48 days after the end of infusion of
the last IFOS. Serum amylase/lipase levels were 600/
4,475 U/L, compatible with acute pancreatitis. Mag-
netic resonance cholangiopancreatography revealed
pancreatitis grade C, without dilatation of the pancre-
atic duct. The patient received supportive treatment,
and amylase/lipase levels decreased to 80/366 U/L
4 days later. Due to improvement in his general con-
dition, he started oral intake. However, abdominal pain
developed again and elevation of amylase/lipase levels
to 879/11,610U/L was noted. Under supportive care,
amylase/lipase returned to normal range 18 days later
(Figure 2).
The whole chemotherapeutic regimen was com-
pleted in July 2005. Currently, he is well and being
followed up as an outpatient.
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Figure 1. (A) Kidney, ureter and bladder show colon cutoff sign (arrows). (B,C) Computed tomography postcontrast shows swelling of
the pancreas and peripancreatic fat stranding. Fluid has accumulated in the peripancreatic area (small arrows), lesser sac, paraduodenal
space (big arrow), and left anterior pararenal space (arrowheads). The findings were compatible with acute pancreatitis grade E
(Balthazar’s severity grade).
Figure 2. Acute pancreatitis with elevation of amylase and lipase
levels after administration of the 3rd and 6th course of ifosfamide.
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Discussion
Without rechallenge, diagnosis of drug-induced pancre-
atitis is difficult. Though odansetron and dexametha-
sone could cause acute pancreatitis, both anti-emetics
had been prescribed during every course of chemother-
apy.7,8 Besides, amphotericin B and meropenem, used
for neutropenic fever before the second episode of pan-
creatitis in our patient, seemed to have no association
with pancreatitis. This patient was young, on regular
diet and not overweight. He denied history of smoking,
alcohol or gallstone. Before he suffered both episodes
of acute pancreatitis, he had no signs of viral infection.
Therefore, there was no further study for virus. Hyper-
lipidemia and hypercalcemia were both excluded by
laboratory results. Imaging studies, including CT and
magnetic resonance cholangiopancreatography, elimi-
nated the possibility of neoplasm, gallstone, or pancreas
divisum. Notably, both his episodes happened after
chemotherapy with IFOS. The 1st episode developed
1 day after the end of IFOS infusion, while the 2nd was
noticed 48 days later. Since other possible causes of
pancreatitis were excluded, IFOS should account for
the cause of pancreatitis.
As to the pathogenesis, the 1st episode of pancre-
atitis 1 day after the end of infusion of IFOS could be
an allergic reaction or due to direct toxicity. However,
delayed onset of the 2nd episode of pancreatitis may
be an immunologically mediated allergic reaction that
may develop a few weeks after administration of the
drug.8 However, further study of the details is still
warranted.
Additionally, because we do not routinely check
amylase and lipase levels during or after chemotherapy
with IFOS, the prevalence of IFOS-induced pancre-
atitis may be underestimated. This patient did experi-
ence various degrees of abdominal discomfort during
every course of chemotherapy with IFOS. Since ab-
dominal symptoms, such as nausea and vomiting, are
common during chemotherapy, we may not include
the diagnosis of pancreatitis initially. Even though pan-
creatitis develops, patients may show recovery with
poor oral intake for a few days. Thus, we hypothesize
that subclinical pancreatitis associated with IFOS does
occur. This may account for there being no evidence
of acute pancreatitis in our patient after the 4th and 5th
course of IFOS.
There are 2 other case reports of IFOS-induced
pancreatitis in the literature. Izraeli et al5 reported the
1st case in 1994. A 16-year-old girl experienced 2 ep-
isodes of acute pancreatitis, both developed 1 day after
completion of IFOS infusion. The 2nd case was reported
by Gerson et al6 in 1997. A 65-year-old female had
pancreatitis 2 days after the last dose of IFOS. In com-
parison, our patient suffered the 1st episode of acute
pancreatitis 1 day after the end of infusion of IFOS,
similar to the previous reports. Nonetheless, the 
2nd episode in our patient is the most delayed onset.
The characteristics of these 3 patients are summarized
in Table 1.
In these 3 cases, the total dosage of IFOS ranged
from 2.4 to 15 g/m2 and seemed not to be related to
risk or severity of acute pancreatitis. It may be owing
to the limited number of cases.
In conclusion, though most drug-induced pancre-
atitis is self-limited, it could be a potentially serious
complication. IFOS could account for pancreatitis, even
48 days after infusion of the drug.
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